Heart Failure

A study presented at HFSA 2019 Scientific Sessions found that virtual visits were a feasible option that could reduce no-show rates among heart failure patients following hospitalization.

Fast Track designation comes about a month after dapagliflozin received another Fast Track designation for delaying the progression of renal failure and prevent CV and renal death in patients with chronic kidney disease

How new dapagliflozin findings from ESC 2019 and HFSA 2019 shape our understanding of the SGLT-2 inhibitor's benefit.

Investigators present data during the HFSA meeting on how different types of meals at different time impact the body’s circadian rhythm.

Emerging mechanical therapy options have given life to a field which has gone under severe recharacterization in an era of increased obesity.

Hospital costs, length of stay, and even mortality were shown to be significantly cut in TAVR patients with comorbid heart failrue than those without, new data shows.

By doubling the recommended weekly dialysis, patients see a number of benefits, including a reduction in blood pressure and improvements in cardiovascular vibration.

The headline drug class has been quickly added to cardiologists' toolsets, amid more and more phase 3 data.

Despite an embrace of greater patient populations by the FDA, cardiovascular research into stem cell therapy has been slow and burdened.

How do a pair of burgeoning agents influence endocrinology and renal outcomes in cardiovascular care?

In a presentation at the annual HFSA meeting, investigators compare the level of care and ultimate outcomes treating heart failure patients for cardiologists and non-cardiologists.

As safety and efficacy programs advance, clinicians consider the investigative therapy's potential in cardiology.

At the annual HFSA meeting, investigators explain how obstructed sleep apnea and central sleep apnea drive cardiovascular disease.

A new study shows just more than 55% of all heart failure-based trials on ClinicalTrials.gov have shared results since 2008.

Investigators report findings no significant associations between BP control and cardiovascular mortality in patients from differing race/ethnicities with HF, stratified by hypertension treatment.

A post hoc analysis of TOPCAT shows older patients with HFpEF report consistent efficacy with spironolactone, but worsening safety outcomes.

Lab tests confirm low levels of NDMA in the popular heart burn medication, sparking a probe in the US and Europe.

Prior to the start of HFSA, Dr. Murray dives through how the extensive history of heart failure research has lead to today's greatest cardiovascular breakthroughs.

Through clinical trials, investigators find that SGLT2 inhibitors are not only safe, but have several cardiovascular benefits.

Initial PCSK9 inhibitor plus statin therapy helped hospitalized patients achieve LDL-C

A recent study found that county-level poverty prevalence correlated with both heart failure and coronary heart disease mortality rates.

Investigators find that opening all blockages with stents is more beneficial after a heart attack than targeting just the clogged artery causing the event.

New findings from the THEMIS trial show patients with stable coronary artery disease and type 2 diabetes mellitus face major bleeding risks from the combination regimen.

Results of the DAPA-HF study — presented at the ESC Congress 2019, reveal use of dapagliflozin reduce hospitalizations from heart failure and deaths from cardiovascular causes in patients with heart failure with reduced ejection fraction.

Results of the PARAGON HF study, which were presented at ESC Congress 2019, reveal no significant benefit of sacubitril-valsartan compared to valsartan for heart failure with preserved ejection fraction in more than 4,500 patients.